1-7 of 7
Sarah Cooley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation

Clinical Trials & Observations
Daniel Weisdorf, Sarah Cooley, Tao Wang, Elizabeth Trachtenberg, Cynthia Vierra-Green, Stephen Spellman, Jennifer A. Sees, Ashley Spahn, Jenny Vogel, Todd A. Fehniger, Ann E. Woolfrey, Steven M. Devine, Maureen Ross, Edmund K. Waller, Ronald M. Sobecks, Joseph McGuirk, Betul Oran, Sherif S. Farag, Tsiporah Shore, Koen Van Besien, Steven G. E. Marsh, Lisbeth A. Guethlein, Peter Parham, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2020) 4 (4): 740–754.
https://doi.org/10.1182/bloodadvances.2019001053
Published: 2020
Includes: Supplemental data
Journal Articles

The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples

Clinical Trials & Observations
Armin Rashidi, Xianghua Luo, Sarah Cooley, Claudio Anasetti, Edmund K. Waller, Claudio G. Brunstein, Frank Cichocki, Daniel J. Weisdorf, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2019) 3 (16): 2465–2469.
https://doi.org/10.1182/bloodadvances.2019000298
Published: 2019
Includes: Supplemental data
Journal Articles

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

Clinical Trials & Observations
Sarah Cooley, Fiona He, Veronika Bachanova, Gregory M. Vercellotti, Todd E. DeFor, Julie M. Curtsinger, Paul Robertson, Bartosz Grzywacz, Kevin C. Conlon, Thomas A. Waldmann, David H. McKenna, Bruce R. Blazar, Daniel J. Weisdorf, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1970–1980.
https://doi.org/10.1182/bloodadvances.2018028332
Published: 2019
Includes: Supplemental data
Journal Articles

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL

Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F. Kaminski, Sarah Cooley, Daniel J. Weisdorf, Daniel A. Vallera, Jeffrey S. Miller, Veronika Bachanova
Journal: Blood Advances
Blood Adv (2019) 3 (6): 897–907.
https://doi.org/10.1182/bloodadvances.2018029371
Published: 2019
Includes: Supplemental data
Journal Articles

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells

Hyun Don Yun, Martin Felices, Daniel A. Vallera, Peter Hinderlie, Sarah Cooley, Michel Arock, Jason Gotlib, Celalettin Ustun, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2018) 2 (13): 1580–1584.
https://doi.org/10.1182/bloodadvances.2018018176
Published: 2018
Includes: Supplemental data
Journal Articles

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS

Dhifaf Sarhan, Ludwig Brandt, Martin Felices, Karolin Guldevall, Todd Lenvik, Peter Hinderlie, Julie Curtsinger, Erica Warlick, Stephen R. Spellman, Bruce R. Blazar, Daniel J. Weisdorf, Sarah Cooley, Daniel A. Vallera, Björn Önfelt, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2018) 2 (12): 1459–1469.
https://doi.org/10.1182/bloodadvances.2017012369
Published: 2018
Includes: Multimedia, Supplemental data
Journal Articles

Fewer circulating natural killer cells 28 days after double cord blood transplantation predicts inferior survival and IL-15 response

Rachel J. Bergerson, Robin Williams, Hongbo Wang, Ryan Shanley, Gretchen Colbenson, Alyssa Kerber, Sarah Cooley, Julie M. Curtsinger, Martin Felices, Jeffrey S. Miller, Michael R. Verneris
Journal: Blood Advances
Blood Adv (2016) 1 (3): 208–218.
https://doi.org/10.1182/bloodadvances.2016000158
Published: 2016
Includes: Supplemental data